| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Assessment of benefits and risks in development of targeted therapies for cancer – The view of regulatory authorities
|
Pignatti, Francesco
|
|
2015
|
9 |
5 |
p. 1034-1041
8 p.
|
article
|
| 2 |
Biomarker validation and testing
|
Hayes, Daniel F.
|
|
2015
|
9 |
5 |
p. 960-966
7 p.
|
article
|
| 3 |
Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug development
|
Jönsson, Bengt
|
|
2015
|
9 |
5 |
p. 1025-1033
9 p.
|
article
|
| 4 |
Cancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approaches
|
Serrano, Davide
|
|
2015
|
9 |
5 |
p. 1008-1017
10 p.
|
article
|
| 5 |
Early phase clinical trials to identify optimal dosing and safety
|
Cook, Natalie
|
|
2015
|
9 |
5 |
p. 997-1007
11 p.
|
article
|
| 6 |
Editorial Board
|
|
|
2015
|
9 |
5 |
p. ii-
1 p.
|
article
|
| 7 |
Emerging uses of patient generated health data in clinical research
|
Wood, William A.
|
|
2015
|
9 |
5 |
p. 1018-1024
7 p.
|
article
|
| 8 |
Hurdles on the road to personalized medicine
|
Tursz, Thomas
|
|
2015
|
9 |
5 |
p. 935-939
5 p.
|
article
|
| 9 |
Innovative clinical trials for development of personalized cancer medicine
|
Mendelsohn, John
|
|
2015
|
9 |
5 |
p. 933-934
2 p.
|
article
|
| 10 |
Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity
|
Catenacci, Daniel V.T.
|
|
2015
|
9 |
5 |
p. 967-996
30 p.
|
article
|
| 11 |
Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test
|
Dienstmann, Rodrigo
|
|
2015
|
9 |
5 |
p. 940-950
11 p.
|
article
|
| 12 |
The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research
|
Berry, Donald A.
|
|
2015
|
9 |
5 |
p. 951-959
9 p.
|
article
|
Journal description